Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
, Yuan Wang 2, Kenneth Ndebele 3, Qiang Zhi 5, Fei-Hu Chen 2, Yu-Zhen Wang 1, Sareh Parangi 4,*1 School of Life Science, University of Science and Technology of China, Hefei 230027, China
2 Laboratory of Molecular Biology & Department of Pharmacology and Pharmaceutical Science, Anhui Medical University, Hefei 230032, China
3 Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center & Harvard Medical School, 99 Brookline Ave, Boston, MA 02215, USA
4 Department of Surgery, Beth Israel Deaconess Medical Center & Harvard Medical School, 99 Brookline Ave, Boston, MA 02215, USA
5 Anhui Sunny Biotech Institute, Hefei 230088, China
Abstract
Apoptosis of vascular endothelial cells is associated with the regression of angiogenesis. Endostatin is a potential anti-angiogenic drug, but the effects of endostatin on apoptotic machinery in endothelial cells largely remain unclear. In the present study, human endostatin was expressed in E. Coli to induce apoptosis in endothelial cells. It was found that the expressed human endostatin specifically affected the viability of the ECV 304 in a dose-dependent manner. Endostatin induced apoptosis in these cells in a caspase-dependent manner, and endostatin-mediated apoptosis is associated with several apoptotic signaling pathways including overloading of intracellular magnesium and calcium, as well as regulation of p53 and Bcl 2 expression.
Keywords
- Recombinant Human Endostatin
- Endothelial Cells
- Proliferation
- Apoptosis
- Molecular Signaling
- p53 Expression
- Intracellular calcium and magnesium